Skip to main content

Table 2 Clinical Characteristics and univariate logistics analysis of risk factors for 30-day mortality of patients diagnosed with CoNS bacteraemia

From: The species distribution, antimicrobial resistance and risk factors for poor outcome of coagulase-negative staphylococci bacteraemia in China

 

Total

n = 157

Survival

n = 137

Non-survival

n = 20

OR

95% CI

p-value

Age

64.0 (48.0–80.0)

62.0 (48.0–80.0)

72.0 (62.8–80.2)

1.0

1.0–1.0

0.112

 ≥60 years

92 (58.6%)

76 (55.5%)

16 (80.0%)

3.2

1.0–10.1

0.046*

 < 60 years

65 (41.4%)

61 (44.5%)

4 (20.0%)

   

Gender

 female

49 (31.2%)

42 (30.7%)

7 (35%)

1.2

0.5–3.3

0.696

 male

108 (68.8%)

95 (69.3%)

13 (65.0%)

   

Residence in ICU

66 (42.0%)

52 (38.0%)

14 (70.0%)

3.8

1.4–10.5

0.010*

APACHE II score

12.0 (6.0–20.0)

11.0 (1.0–36.0)

20.0 (6.0–32.0)

1.1

1.0–1.2

0.002*

qSOFA score

 2 and 3

36 (22.9%)

26 (19.0%)

10 (50.0%)

4.3

1.6–11.3

0.004*

 0 and 1

121 (77.1%)

111 (81.0%)

10 (50.0%)

   

Prior hospital stay length

15.0 (4.0–35.0)

13.0 (4.0–31.0)

30.5 (5.8–46.2)

2.8

1.0–1.0

0.707

 ≥28 days

53 (33.8%)

42 (31%)

11 (55%)

2.8

1.1–7.2

0.036*

 < 28 days

104 (66.2%)

95 (69.3%)

9 (45.0%)

   

Comorbidities

 Cardiovascular disease

95 (60.5%)

82 (59.9%)

13 (65.0%)

1.2

0.5–3.3

0.661

 Pneumonia

73 (46.5%)

59 (43.1%)

14 (70.0%)

3.1

1.1–8.5

0.030*

 Cerebrovascular disease

46 (29.3%)

42 (30.7%)

4 (20.0%)

0.6

0.2–1.8

0.333

 Diabetes mellitus

36 (22.9%)

32 (23.4%)

4 (20.0%)

0.8

0.3–2.6

0.739

 Chronic liver failure

29 (18.5%)

20 (14.6%)

9 (45.0%)

4.8

1.8–13.0

0.002*

 Chronic renal failure

27 (17.2%)

18 (13.1%)

9 (45.0%)

5.4

2.0–14.9

0.001*

 Solid tumor

28 (17.8%)

24 (17.5%)

4 (20.0%)

1.2

0.4–3.8

0.787

 Hematologic malignancy

11 (7.0%)

9 (6.6%)

2 (10.0%)

1.6

0.3–7.9

0.577

 Neutropenia

12 (7.6%)

11 (8.0%)

1 (5.0%)

0.6

0.1–4.9

0.637

Prior treatments

 Indwelling CVC

88 (56.1%)

74 (54.0%)

14 (70.0%)

2.0

0.7–5.5

0.184

 Indwelling urinary catheter

67 (42.7%)

57 (41.6%)

10 (50.0%)

1.4

0.5–3.6

0.480

 Invasive MV

38 (24.2%)

33 (24.1%)

5 (25.0%)

1.1

0.4–3.1

0.929

 Broad-spectrum antibiotics

31 (19.7%)

45 (32.8%)

6 (30.0%)

0.9

0.3–2.4

0.800

 Surgery

28 (17.8%)

26 (19.0%)

2 (10.0%)

0.5

0.1–2.2

0.337

 Renal replacement therapy

9 (5.7%)

7 (5.1%)

2 (10.0%)

2.1

0.4–10.7

0.389

 Chemotherapy

4 (2.5%)

3 (2.2%)

1 (5.0%)

2.4

0.2–23.8

0.469

Laboratory test results

 CRP (mg/dL)

3.9 (2.3–8.6)

3.9 (0.1–29.4)

3.9 (1.2–78.2)

1.0

1.0–1.1

0.175

 Leukocyte (×109/L)

8.2 (5.2–11.9)

8.2 (4.7–12.1)

8.3 (6.2–11.1)

1.0

0.9–1.1

0.706

 Neutrophils (×109/L)

6.5 (3.6–9.5)

6.6 (3.3–9.9)

6.3 (4.1–9.1)

1.0

0.9–1.1

0.643

 ALT (U/L)

24.6 (13.5–41.9)

24.4 (3.7–147.0)

30.2 (1.7–419.1)

1.0

1.0–1.0

0.024*

 SCr (μmol/L)

63.5 (51.3–83.6)

62.1 (22.4–1392.0)

69.0 (37.9–791.0)

1.0

1.0–1.0

0.690

Appropriate empirical antibiotic therapy

132 (84.1%)

117 (85.4%)

15 (75.0%)

0.5

0.2–1.6

0.242

 Vancomycin

40 (25.5%)

39 (28.5%)

1 (5.0%)

0.1

0.0–1.0

0.052

 Carbapenems

33 (21.0%)

27 (19.7%)

6 (30.0%)

1.7

0.6–5.0

0.296

 Linezolid

4 (2.5%)

4

0

–

–

–

  1. OR odds ratio, 95% CI confidence interval, CVC central venous catheter, MV mechanical ventilation, CRP c-reactive protein, ALT alanine aminotransferase, SCr serum creatinine, APACHE II acute physiology and chronic health evaluation (ii), qSOFA quick sepsis related organ failure assessment
  2. *Bold font means that the risk factor was statistically p < 0.05 in the univariate logistics analysis and was included in the multivariate logistics analysis